Earnings summaries and quarterly performance for Pelthos Therapeutics.
Research analysts covering Pelthos Therapeutics.
Recent press releases and 8-K filings for PTHS.
Pelthos Therapeutics Inc. details Q4 2025 performance, director compensation changes, and product pipeline updates
PTHS
Executive Compensation
Product Launch
M&A
- Pelthos Therapeutics Inc. approved changes to its non-employee director compensation policy, effective January 1, 2026, which include an increased annual cash retainer for the Non-Executive Chairman to $60,000 and new annual cash retainer fees for service on the Audit, Compensation, and Nominating and Corporate Governance Committees.
- The company reported strong early uptake for Zelsuvmi, launched in July 2025, with 6,233 dispensed units and 2,174 prescribers in Q4 2025. Covered lives for Zelsuvmi significantly increased by January 2026, reaching 60% for commercial and 83% for Medicaid.
- Pelthos acquired Xepi in October 2025 and Xeglyze in December 2025, with expected relaunches in late 2026 and the first half of 2027, respectively.
- The company forecasts a peak net revenue of $175M per annum for Zelsuvmi alone by 2028. As of January 9, 2026, Pelthos had a market capitalization of ~$230M and $14.2M in cash at the close of Q3 2025.
Jan 12, 2026, 9:31 PM
Pelthos Therapeutics Provides Update on Zelzuvmi Launch and Xepi Acquisition
PTHS
Product Launch
M&A
Guidance Update
- Pelthos Therapeutics announced a significant payer win for Zelzuvmi, covering approximately 20 million lives, with the majority becoming effective today, December 4, 2025.
- Zelzuvmi, launched on July 10, 2025, recorded 2,700 prescriptions in Q3 2025 and 2,200 prescriptions in October 2025, contributing to an October net revenue run rate of approximately $35 million annually. The company expanded its salesforce by 14 reps and 2 managers, bringing the total to 64 reps and 8 managers.
- The gross-to-net for Zelzuvmi was 25.3% in Q3 2025, with expectations to rise to the high 20s in Q4 2025 and stabilize in the mid-to-high 30s in 2026.
- The company recently acquired Xepi (Ozenoxacin), a topical product for impetigo, which addresses approximately 3 million cases annually and targets the same call audience as Zelzuvmi.
- Zelzuvmi's exclusivity is currently until 2035, with an expected extension to mid-2037, while Xepi's exclusivity runs until early 2032.
Dec 4, 2025, 2:30 PM
Pelthos Therapeutics Announces Major Payer Win for Zelzuvmi and Strong Early Sales
PTHS
Product Launch
Revenue Acceleration/Inflection
M&A
- Pelthos Therapeutics secured a major payer win for its lead asset, Zelzuvmi, covering approximately 20 million lives, with the majority of coverage becoming effective on December 4, 2025.
- Zelzuvmi, launched in July 2025, demonstrated strong early commercial success with 2,700 prescriptions in Q3 2025 and 2,200 prescriptions in October 2025, marking a 41% increase over September. This performance suggests an annual net revenue run rate of approximately $35 million based on October's figures.
- The company reported a gross-to-net of 25.3% for Zelzuvmi in Q3 2025, with projections for it to increase to the high 20s in Q4 2025 and stabilize in the mid- to high 30s in 2026.
- Pelthos expanded its salesforce from 50 to 64 representatives and 8 managers to cover all major metropolitan areas, having achieved a rapid return on investment by paying for the salesforce within nine weeks of launch.
- The company acquired Xepi (ozenoxacin), a topical treatment for impetigo, which presents 3 million annual cases and offers significant synergy by leveraging Pelthos's existing commercial infrastructure and call audience.
Dec 4, 2025, 2:30 PM
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
PTHS
Earnings
Product Launch
M&A
- Pelthos Therapeutics Inc. reported net revenues of $7.1 million from its lead product, ZELSUVMI, during its first quarter of commercial operations for the three months ended September 30, 2025.
- The company recorded a net loss of $16.2 million, or $5.30 per basic and fully diluted common share, for the third quarter of fiscal 2025.
- As of September 30, 2025, cash and cash equivalents totaled $14.2 million.
- Following the quarter, Pelthos completed the acquisition of XEPI and secured an $18 million private convertible notes financing in November 2025, building on a $50.1 million equity private placement to support ZELSUVMI's launch.
Nov 13, 2025, 11:50 AM
Pelthos Therapeutics Acquires Xepi® and Secures $18 Million Convertible Notes Financing
PTHS
M&A
Debt Issuance
New Projects/Investments
- Pelthos Therapeutics Inc. acquired the U.S. commercialization rights to Xepi® (ozenoxacin) Cream, 1%, an FDA-approved topical treatment for impetigo, from Biofrontera Inc. and Ferrer Internacional S.A..
- The acquisition includes upfront payments of $3.0 million to Biofrontera and $1.2 million to Ferrer, with Pelthos planning to re-launch Xepi in late 2026.
- To finance the acquisition, re-launch of Xepi, accelerate ZELSUVMI commercialization, and for general working capital, Pelthos closed an $18 million private convertible notes financing with existing investors.
- These notes carry an 8.5% annual interest rate, mature on November 6, 2027, and have an initial conversion price of $34.442.
Nov 7, 2025, 1:01 PM
Pelthos Therapeutics Inc. Provides Update on Zelsuvmi Commercial Launch
PTHS
Product Launch
Guidance Update
- Pelthos Therapeutics Inc. (PTHS) commercially launched Zelsuvmi in July 2025 as the first and only at-home treatment for Molluscum contagiosum (MC).
- Zelsuvmi targets a significant market, with up to 6 million new annual cases in the U.S. and a total addressable market potential exceeding $20 billion.
- The company forecasts peak net revenues of $175 million per annum by 2028 for Zelsuvmi.
- During its early launch phase in Q3 2025, Zelsuvmi recorded 2,716 TRx Units and attracted 1,169 unique prescribers.
- Clinical trials demonstrated strong efficacy, with a mean lesion count reduction of 58% and complete clearance in 32.4% of patients at week 12.
Oct 14, 2025, 11:46 AM
Pelthos Therapeutics Inc. Launches ZELSUVMI™ and Prepares for Wells Fargo Conference
PTHS
Product Launch
New Projects/Investments
Guidance Update
- Pelthos Therapeutics Inc. commercially launched ZELSUVMI™ (berdazimer) topical gel, 10.3%, in July 2025. ZELSUVMI™ is the first and only FDA-approved at-home treatment for molluscum contagiosum, having received FDA approval in January 2024.
- The company forecasts peak net revenue of $175 million per annum by 2028 for ZELSUVMI™, targeting a total addressable market for molluscum contagiosum in excess of $20 billion with up to 6 million annual cases in the U.S..
- In its early launch phase, ZELSUVMI™ recorded 892 TRx Units and 501 unique prescribers by August 22, 2025.
- CEO Scott Plesha and CFO Frank Knuettel are scheduled to present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, to provide updates on the product pipeline and the commercial launch of ZELSUVMI™.
Sep 3, 2025, 12:31 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more